The research group led by professor Mart Saarma, Director of the Institute of Biotechnology, University of Helsinki, has discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor). CDNF was shown to protect and even rescue damaged dopamine neurons in an experimental model of Parkinson’s disease in studies performed by the research group of professor Raimo K. Tuominen, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. More importantly, also the function of the neurons was recovered after an experimental lesion of the dopamine neurons in Substantia Nigra.
The findings of this research may be of great importance for the development of new treatment strategies for Parkinson’s disease. The results of this study will be published in “Nature” on July 5th, 2007.
Approximately one percent of people aged over 60 get Parkinson’s disease all over the World. The demographic change with increasing number of elderly people will lead in doubling of the number of Parkinsonian patients also in Finland during 2005 – 2030. Typical symptoms in Parkinson’s disease are those of muscle rigidity, tremor, and slowness of movement. They are a consequence of the degeneration of dopamine nerves projecting from Substantia Nigra to Caudate Putamen (also called Striatum). The clinical symptoms manifest when approximately 70 % of the dopamine nerves have been destroyed. Degeneration of the dopamine nerves progresses slowly, and in time the difficulties in movement becomes a major factor reducing the quality of life of these patients.
Current drug treatment of Parkinson’s disease aims at increasing dopamine concentration and / or activation of dopamine receptors in the brain. Due to the progression of the nerve degeneration the drug therapy gradually becomes less effective. Neurotrophic factors which could slow down or even halt the progression of the degeneration of dopamine nerves have been in the focus as a possible new treatment for Parkinson’s disease. Glial cell- line derived neurotrophic fctor (GDNF) is one example of such a promising growth factor. Indeed, it was shown to have beneficial effects in a clinical trial in Parkinsonian patients suffering from severe symptoms. However, due to adverse effects the clinical trials have been stopped, even though some of the patients would have continued the therapy. Even so, the clinical trials on GDNF gave the proof of concept for the use of neurotrophic factorstreatment of neurodegenerative diseases. Therefore it is very important to search for new growth factors with similar efficacy as GDNF, but with better tolerability.
Conserved dopamine neurotrophic (CDNF) factor discovered and characterized in this study is well conserved in the evolution. It belongs to a CDNF/MANF family of proteins, which is the first evolutionarily conserved family of neurotrophic factors having a representative also in invertebrate animals (MANF = mesencephalic astrocyte derived neurotrophic factor).
In an experimental model of Parkinson’s disease, a neurotoxin 6-OHDA was injected on one side of the brain into the striatum of rats. This toxin causes a progressive degeneration of dopamine nerves similar to that observed in Parkinsons disease. Upon activation of dopamine nerves of the brain by drugs, these animals show a movement disorder, a circling behaviour, which reflects an imbalance of dopamine activity of the brain hemispheres.
A single injection of CDNF six hours before the toxin delivery into the striatum significantly prevented the degeneration of dopamine nerves in the brain and also the turning behavior was normalized. When administered four weeks after the toxin, situation mimicking a progression of the nerve degeneration in patients, injection of CDNF into Striatum was able to prevent the degeneration of dopaminergic neurons and cure the behavioral imbalance.
The results of the present study show that CDNF is a very promising new neurotrophic factor with a significant neuroprotective and neurorestorative effects on dopamine nerves in the brain. It may have significant potential in the treatment of Parkinson’s disease in the future as a neuro protective or even neurorestorative therapy.
Title of the article in “Nature”: Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo
Authors: Päivi Lindholm1, Merja H. Voutilainen2, Juha Laurén1†, Johan Peränen1, Veli-Matti Leppänen1, Jaan-Olle Andressoo1, Maria Lindahl1, Sanna Janhunen2#, Nisse Kalkkinen1, Tõnis Timmusk1,3, Raimo K. Tuominen2 & Mart Saarma1
Ms. Päivi Lindholm, M.Sc., had a central role in the discovery of CDNF and Mrs. Merja H. Vuotilainen (born Kauppinen), M.Sc. performed the studies on experimental model of Parkinson’s disease.
For further information, please contact:Prof. Mart Saarma (050 5002726)
Terttu Nurro | alfa
The genes are not to blame
20.07.2018 | Technische Universität München
Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.
The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
20.07.2018 | Power and Electrical Engineering
20.07.2018 | Information Technology
20.07.2018 | Materials Sciences